MedTrace Logo

Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)

NCT05697588 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2025-07-24

No results posted yet for this study

Summary

Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.

Conditions

  • Biomarkers
  • MCI Conversion to Dementia

Sponsors & Collaborators

  • Beihang University

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Chongqing Medical University

    collaborator OTHER

  • Tianjin Huanhu Hospital

    collaborator OTHER

  • Affiliated Zhongshan Hospital of Dalian University

    collaborator OTHER

  • First Hospital of Shijiazhuang City

    collaborator OTHER

  • Jilin University

    collaborator OTHER

  • Cuibai Wei，Clinical Professor

    lead OTHER

Principal Investigators

  • Cuibai Wei · Xuan Wu Hospital of Capital Medical University

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2028-02-28
Completion
2028-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05697588 on ClinicalTrials.gov